British Biotech Pharmaceuticals Limited

British Bio-technology Limited

Zoe Marie Spavold

Mark Whittaker

Raymond Paul Beckett

Michael George Hunter

John Martin Clements

Lisa Marie Pratt

Steven Launchbury

Stephen John Davies

Andrew Miller

Fionna Mitchell Martin

Alan H Davidson

Paul Raymond Beckett

Stephen Arthur Bowles

Philip Huxley

Compounds of formula (I) or a pharmaceutically or veterinarily acceptable salts thereof wherein Rrepresents hydrogen, C-Calkyl or C-Calkyl substituted by one or more halogen atoms; Rrepresents a group R-(ALK)-, and A represents (i) a group of formula (IA): wherein the compounds inhibit the activity of bacterial PDF enzyme.

Antibacterial agents

A method for the treatment of bacterial infections in humans and non-human mammals, which comprises inhibiting bacterial growth by administering to a subject an antibacterially effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof: 

Hydroxamic acid derivatives as antibacterials

A compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof for the inhibition of activity of bacterial PDF enzyme: wherein A represents a group of formula (IA) or (IB) and wherein Ris hydrogen, Ris n-butyl, benzyl or cyclopentylmethyl, Ris hydrogen, Ris tert-butyl, iso-butyl, benzyl or methyl, Ris hydrogen or methyl and Ris methyl.

A method for the treatment of bacterial infections in humans and non-human mammals, which comprises inhibiting bacterial growth by administering to a subject an antibacterially effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof:

Selected compounds of formula (I) are antibacterial agents: formula (I) wherein Rrepresents a substituted or unsubstituted C-Calkyl, cycloalkyl (C-Calkyl)- or aryl (C-Calkyl)-group, and A represents a group of formula (IA), or (IB) wherein Rrepresents the side chain of a natural or non-natural alpha amino acid, and Rand Rare each independently hydrogen or C-Calkyl, heterocyclic or aryl (C-Calkyl)-, Rand Rwhen taken together with the nitrogen atom to which they are attached from an optionally substituted saturated heterocyclic ring of 3 to 8 atoms which ring is optionally fused to a carbocyclic or second heterocyclic ring

Compounds of formula (I) are antibacterial agents wherein: R and R , taken together with the carbon atoms to which they are respectively attached, form an optionally substituted saturated carbocyclic or heterocyclic ring of 5 to 16 atoms, which may be benz-fused or fused to a second optionally substituted saturated carbocyclic or heterocyclic ring of 5 to 16 atoms; and R and R are as defined in the specification.

Compounds of formula (I) are antibacterials wherein: R represents hydrogen, or C -C alkyl or C -C alkyl substituted by one or more halogen atoms; R represents a group R &mdash;(X) &mdash;(ALK) &mdash; wherein R represents hydrogen, or a C -C alkyl, C -C alkenyl, C -C alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C -C )alkyl, (C -C )alkoxy, hydroxy, mercapto, (C -C )alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, cyano, nitro, &mdash;COOH, &mdash;CONH , &mdash;COOR , &mdash;NHCOR , &mdash;CONHR , &mdash;NHR , &mdash;NR R , or &mdash;CONR R wherein R and R are independently a (C -C )alkyl group, and ALK represents a straight or branched divalent C -C alkylene, C -C alkenylene, or C -C alkynylene radical, and may be interrupted by one or more non-adjacent &mdash;NH&mdash;, &mdash;O&mdash; or &mdash;S&mdash; linkages, X represents &mdash;NH&mdash;, &mdash;O&mdash; or &mdash;S&mdash;, and m and n are independently 0 or 1; and A represents a group as defined in the specification.

Matrix metalloproteinase inhibitors

Derivatives of succinamide and their use as metalloproteinase inhibitor

Derivatives of succinamide and their use as metalloproteinase inhibitors

Compound of formula (I) ##STR1## wherein Ar represents an optionally substituted phenyl or heteroaryl group, m is 1 or 2, n is 0, 1, 2, 3 or 4, X represents --COOH or --CONHOH and R.sub.1, R.sub.3 and Y are as defined in the specification,are inhibitors of metalloproteinases involved in tissue degradation.

Metalloproteinase inhibitors

Lactol PAF antagonists

Compounds of general formula I; ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are variables. These compounds are antagonists of platelet activating factor (PAF) and as such are useful in the treatment or amelioration of various diseases or disorders mediated by PAF.

Growing community of inventors

Oxford, United Kingdom

Zoe Marie Spavold